550369-44-3

Basic information

• Product Name: 4-Piperidinol, 4-ethyl-
• Synonyms: 4-ethylpiperidin-4-ol
• CAS NO: 550369-44-3
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2
• Mol File: 550369-44-3.mol

Chemical Properties

• Boiling Point: 204.8±15.0 °C(Predicted)
• Appearance: /
• Density: 0.953±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 15.01±0.20(Predicted)
• CAS DataBase Reference: 4-Piperidinol, 4-ethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinol, 4-ethyl-(550369-44-3)
• EPA Substance Registry System: 4-Piperidinol, 4-ethyl-(550369-44-3)

Safety Data

• Hazardous Substances Data: 550369-44-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidinol, 4-ethylis used as a building block in the synthesis of various pharmaceuticals and other organic compounds. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Piperidinol, 4-ethylis utilized in the manufacture of certain agrochemicals. Its properties make it suitable for use in the development of products that can enhance crop protection and improve agricultural yields.
Used in Chemical Manufacturing:
4-Piperidinol, 4-ethylserves as a solvent in the production of resins and dyes. Its solvent properties are beneficial in the chemical manufacturing process, ensuring the efficient creation of high-quality products.
Used in Medicinal Research:
4-Piperidinol, 4-ethylis known to have some medicinal properties and has been studied for its potential as an analgesic and anticonvulsant. Its ability to alleviate pain and prevent seizures makes it a promising candidate for further research and development in the medical field.
It is important to handle 4-Piperidinol, 4-ethylwith care, as it can be toxic and should only be used by trained professionals in a controlled laboratory setting to ensure safety and proper utilization of its properties.

Upstream product

• 440101-11-1 1-benzyl-4-ethyl-4-hydroxypiperidine 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1374567-37-9 C₂₄H₂₇ClN₄O₃ 
• 1374855-92-1 (E)-3-(4-chlorophenyl)-N-(2-(4-ethyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1429504-80-2 (4-ethyl-4-hydroxypiperidin-1-yl)(5-methyl-2-(pyridin-4-yl)-phenyl)methanone 

Relevant articles and documents

Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor

Twenty eight new aryloxybenzene analogues were synthesized and their in vitro binding potencies toward S1PR2 were determined using a [32P]S1P competitive binding assay. Out of these new analogues, three compounds, 28c (IC50 = 29.9 ± 3.9 nM), 28e (IC50 = 14.6 ± 1.5 nM), and 28g (IC50 = 38.5 ± 6.3 nM) exhibited high binding potency toward S1PR2 and high selectivity over the other four receptor subtypes (S1PR1, 3, 4, and 5; IC50 > 1000 nM). Each of the three potent compounds 28c, 28e, and 28g contains a fluorine atom that will allow to develop F-18 labeled PET radiotracers for imaging S1PR2.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2

Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.

Benzimidazolidinone derivatives as muscarinic agents

Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.